On Jul. 9, 2021, Humanigen announced its submission for Marketing Authorization for lenzilumab in COVID-19, begun in Jun. 2021, had been accepted by the United Kingdomﾒs (UKﾒs) Medicines and Healthcare Products Regulatory Agency (MHRA) for expedited COVID-related rolling review, with assessment expected to occur more rapidly than a standard rolling review.